Intensity Therapeutics (NASDAQ:INTS – Get Free Report) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Intensity Therapeutics (NASDAQ:INTS – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. Get Intensity Therapeutics alerts:Intensity Therapeutics Trading Down 1.1%Shares of Intensity Therapeutics stock opened at $4.21 on Wednesday. Intensity Therapeutics Company Profile(Get Free Report)Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. Featured StoriesReceive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.